Trial Profile
A Real-World, Retrospective study to evaluate the safety and efficacy of Cabozantinib in patients with Metastatic Renal Cell Carcinoma (mRCC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jul 2018
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 02 Jul 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology